The Winterthur-based medtech start-up Medyria has secured CHF 1.5 million in a new round of financing. Under the brand name PyCath, Medyria is developing the next generation of microcatheters for invasive cardiological diagnosis.
Medyria has completed a financing round worth CHF 1.5 million. It was led by the Lisbon-based Portuguese subsidiary of Madrid-based venture capital fund Buenavista. According to a press release, existing investors also participated.
It goes on to say that this “significant investment” will drive forward Medyria’s PyCath project and marks a decisive moment for the growth of the medical technology company based in Technopark Winterthur. Under the PyCath brand name, Medyria is developing the next generation of microcatheters for invasive cardiological diagnosis. These catheters feature IP-protected sensors that measure blood flow velocity in the coronary arteries, which is an important indicator of key parameters such as aortic pressure and microvascular resistance.
According to the information provided, the newly raised funds will be used to initiate the first clinical trials in humans. These trials are intended to validate the efficacy and safety of the system under real-world conditions. In addition, “a significant portion” of the investment will go toward preparing and submitting the application for approval to the Food and Drug Administration (FDA). “This funding is critical for us to advance our clinical development and regulatory efforts, bringing us one step closer to delivering a transformative solution for patients and healthcare providers worldwide,” said Medyria CEO Mauro M. Sette.
In connection with this financing, Medyria also announces the establishment of Medyria Atlantic, based in the Portuguese city of Obidos. The subsidiary will serve as a strategic hub, overseeing clinical activities, leading commercial development across Europe, and managing a significant portion of PyCath production as well as ongoing research and development. ce/mm
